Uroplasty (NASDAQ: UPI) and Smith & Nephew (NYSE:SNN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Institutional and Insider Ownership
6.4% of Smith & Nephew shares are owned by institutional investors. 1.0% of Smith & Nephew shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This is a breakdown of current ratings for Uroplasty and Smith & Nephew, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Smith & Nephew||0||3||1||0||2.25|
Smith & Nephew has a consensus price target of $42.00, indicating a potential upside of 20.52%. Given Smith & Nephew’s higher probable upside, analysts clearly believe Smith & Nephew is more favorable than Uroplasty.
Smith & Nephew pays an annual dividend of $0.61 per share and has a dividend yield of 1.8%. Uroplasty does not pay a dividend. Smith & Nephew has increased its dividend for 4 consecutive years.
Volatility and Risk
Uroplasty has a beta of -1.26, suggesting that its share price is 226% less volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
Earnings and Valuation
This table compares Uroplasty and Smith & Nephew’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Smith & Nephew||$4.67 billion||3.26||$784.00 million||N/A||N/A|
Smith & Nephew has higher revenue and earnings than Uroplasty.
This table compares Uroplasty and Smith & Nephew’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Smith & Nephew||N/A||N/A||N/A|
Smith & Nephew beats Uroplasty on 11 of the 11 factors compared between the two stocks.
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
About Smith & Nephew
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices. The Sports Medicine Joint Repair franchise offers surgeons a range of instruments, technologies and implants necessary to perform minimally invasive surgery of the joints, including the repair of soft tissue injuries and degenerative conditions of the knee, hip and shoulder. The AET franchise offers an array of minimally invasive surgery-enabling systems and devices. The Trauma & Extremities franchise supports healthcare professionals with solutions used by surgeons to stabilize severe fractures, correct bone deformities, treat arthritis and heal soft tissue complications.
Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.